Summary: A phase 2/3, study evaluating pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants.
Sponsor: Gilead Sciences, Inc
Principal Investigator: Dr. Godfrey Kigozi
Study site: AMBSO-Masaka Research Site
Update: Screening and recruitment phase